1)Chu DZ, Lang NP, Thompson C, et al:Peritoneal carcinomatosis in non-gynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364-367, 1989
2)Sadeghi B, Arvieux C, Glehen O, et al:Peritoneal carcinomatosis from non-gynecologic malignancies:results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358-363, 2000
3)Jayne DG, Fook S, Loi C, et al:Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545-1550, 2002
4)Mirnezami R, Mehta AM, Chandrakumaran K, et al:Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 111:1500-1508, 2014
5)van Driel WJ, Koole SN, Sikorska K, et al:Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med 378:230-240, 2018
6)Spratt JS, Robert AA, Muskovin M, et al:Clinical Delivery System for Intraperitoneal Hyperthermic Chemotherapy. Cancer Res 40:256-260, 1980
7)Koga S, Hamazoe R, Maeta M, et al:Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 44:1840-1842, 1984
8)Kemmel V, Mercoli HA, Meyer N, et al:Mitomycin C pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol 22(Suppl 3):S873-879, 2015
9)Rodier S, Saint-Lorant G, Guilloit JM, et al:Is hyperthermic intraperitoneal chemotherapy(HIPEC)safe for healthcare workers? Surg Oncol 26:242-251, 2017
10)Quénet F, Elias D, Roca L, et al:A UNICANCER phase Ⅲ trial of hyperthermic intra-peritoneal chemotherapy(HIPEC)for colorectal peritoneal carcinomatosis(PC):PRODIGE 7. J Clin Oncol 36(suppl):LBA 3503, 2018
11)Turaga K, Levine E, Barone R, et al:Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy(HIPEC)in colorectal cancer patients in the United States. Ann Surg Oncol 21:1501-1505, 2014